News about "GSK plc "

GSK's Jemperli Receives FDA Priority Review for dMMR/MSI-H Locally Advanced Rectal Cancer

GSK’s Jemperli has received FDA priority review for previously untreated dMMR/MSI-H locally advanced rectal cancer, following positive phase 2 AZUR-1 results.

GSK Plc | 26/08/2026 | By News Bureau

GSK Receives Japan's First Approval for Bepirovirsen as Functional Cure for Chronic Hepatitis B

Japan’s MHLW approves Hibsago for eligible adults with chronic hepatitis B, following Phase 3 data showing a 19 percent functional cure rate after six months of treatment.

GSK Plc | 25/08/2026 | By News Bureau

Hansoh Pharma Reports Positive Phase 3 Results for Ris-Rez in China

Hansoh Pharma reported positive phase 3 results for Ris-Rez in China, while GSK advances development across lung cancer, prostate cancer and other solid tumors.

GSK Plc | 31/07/2026 | By News Bureau

GSK to Establish New Global R&D Centre in Cambridge to Accelerate Drug Discovery

GSK will establish a 300,000 sq. ft. global R&D centre at the Cambridge Biomedical Campus, bringing together more than 1,000 scientists to accelerate medicines discovery through closer collaboration with leading academic, clinical and biotechnology partners.

GSK Plc | 30/07/2026 | By News Bureau

GSK's Efimosfermin Secures FDA Breakthrough and EMA PRIME Status for MASH Treatment

The dual regulatory designations from US FDA and European Medicines Agency fast-track development of GSK’s investigational liver therapy for metabolic dysfunction-associated steatohepatitis.

GSK Plc | 29/04/2026 | By News Bureau |  196

GSK plc Secures China Approval for Blenrep Combination Therapy in Multiple Myelom

National Medical Products Administration approves Blenrep with bortezomib and dexamethasone for relapsed or refractory patients, backed by strong phase III trial outcomes.

GSK Plc | 21/04/2026 | By News Bureau |  139

GSK plc Secures Japan Orphan Drug Status for Ris-Rez in Small-Cell Lung Cancer

Japan’s health ministry grants orphan drug designation to GSK’s investigational ADC Ris-Rez for SCLC, supported by early clinical data showing durable responses in advanced-stage patients.

GSK Plc | 24/03/2026 | By News Bureau |  186

GSK Secures FDA Approval for Lynavoy, First Treatment for PBC-Related Chronic Itch

FDA approves GSK’s Lynavoy (linerixibat), the first therapy for cholestatic pruritus in primary biliary cholangitis patients, offering significant and sustained itch relief.

GSK Plc | 21/03/2026 | By News Bureau |  190

GSK Reports Real-World Data Showing Strong Effectiveness of RSV Vaccine in Older Adults

New US and Denmark studies presented at ReSViNET 2026 show GSK’s RSV vaccine is associated with reduced hospitalisations and lower risk of severe cardiovascular and respiratory complications in adults aged 60 and above.

GSK Plc | 19/02/2026 | By News Bureau |  208

GSK Wins EU Approval for Exdensur in Severe Asthma and CRSwNP

European Commission clears twice-yearly depemokimab for type 2 inflammation-driven severe asthma and chronic rhinosinusitis with nasal polyps, backed by positive Phase III SWIFT and ANCHOR data.

GSK Plc | 18/02/2026 | By News Bureau |  164